Zobrazeno 1 - 10
of 298
pro vyhledávání: '"Katherine A. Lyseng-Williamson"'
Publikováno v:
Drugs & Therapy Perspectives. 36:539-546
Levosert® (EU)/Liletta® (USA) is a levonorgestrel (LNG)-releasing intrauterine system (IUS) containing 52 mg of LNG. It was the first LNG-releasing IUS approved for use for up to 6 years, with daily LNG release rates being sufficient to provide con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa56174c52841c8d7099ddac70b34578
https://doi.org/10.1007/s40267-020-00794-y
https://doi.org/10.1007/s40267-020-00794-y
Publikováno v:
Drugs & Therapy Perspectives. 36:547-552
Rimegepant orally disintegrating tablets (ODT) for sublingual or oral use (Nurtec™ ODT) are a valuable option for the acute treatment of migraine ± aura in adults, especially those with contraindications, treatment failure, or tolerability issues
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bade341e71cbbd307d4ce9654b6e2ad
https://doi.org/10.1007/s40267-020-00790-2
https://doi.org/10.1007/s40267-020-00790-2
Publikováno v:
Drugs. 80:1723-1730
Trastuzumab emtansine (Kadcyla®), an antibody–drug conjugate of trastuzumab (Herceptin®) connected by a thioether linker to the microtubule inhibitor DM1 (a cytotoxic derivative of maytansine), provides direct intracellular delivery of the potent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ee8474a71b3b9779e6886bf1a42e88a
https://doi.org/10.1007/s40265-020-01408-7
https://doi.org/10.1007/s40265-020-01408-7
Publikováno v:
Drugs & Therapy Perspectives. 36:435-439
Restless legs syndrome (RLS; also known as Willis-Ekbom disease) is a common neurological, sensorimotor disorder. RLS is initially managed with lifestyle modifications, elimination of possible iatrogenic contributors and maintenance of normal-high pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd26e15f29d762b4a51999fbd4a3c231
https://doi.org/10.1007/s40267-020-00773-3
https://doi.org/10.1007/s40267-020-00773-3
Publikováno v:
Drugs & Therapy Perspectives. 36:502-508
Methadone’s pharmacological properties and its numerous routes of administration can make it a useful analgesic option in adults and children with cancer pain. However, careful patient selection and monitoring is needed, especially if methadone is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f41d477207ff300d9ed209999033382
https://doi.org/10.1007/s40267-020-00772-4
https://doi.org/10.1007/s40267-020-00772-4
Publikováno v:
Drugs & Therapy Perspectives. 36:1-11
Prophylactic treatment with aprotinin, a haemostatic antifibrinolytic agent, is indicated to reduce blood loss and blood transfusion in adults with a high risk of major bleeding undergoing primary or repeat isolated coronary artery bypass graft (CABG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60b889001530821b88e4d6010af600e0
https://doi.org/10.1007/s40267-019-00690-0
https://doi.org/10.1007/s40267-019-00690-0
Publikováno v:
Drugs & Therapy Perspectives. 35:529-535
Fexinidazole winthrop (hereafter fexinidazole) is the first all-oral therapy available for the treatment of human African trypanosomiasis (HAT; commonly known as ‘sleeping sickness’). Fexinidazole is a 5-nitroimidazole derivative developed by the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab0f64f7cdfad4031bcd04d24dfacc16
https://doi.org/10.1007/s40267-019-00672-2
https://doi.org/10.1007/s40267-019-00672-2
Publikováno v:
Drugs & Therapy Perspectives. 35:463-469
Oral zinc l-carnosine (Gastrozin®) 75 mg twice daily is an effective gastric mucoprotective option for the treatment and prevention of gastric ulcers. The two components of the chelated compound (i.e. zinc and l-carnosine in a 1:1 ratio) provide ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bde7e5b6ff56220a2ebf6773272e7c4
https://doi.org/10.1007/s40267-019-00667-z
https://doi.org/10.1007/s40267-019-00667-z
Publikováno v:
Drugs & Therapy Perspectives. 35:405-412
Ravulizumab (Ultomiris™) is a humanized monoclonal antibody that inhibits terminal complement C5, thereby reducing hemolysis, inflammation, and thrombosis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab was developed by re-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9b48f4e1700fb2be12d99f4d6f9c729
https://doi.org/10.1007/s40267-019-00663-3
https://doi.org/10.1007/s40267-019-00663-3
Publikováno v:
Drugs & Therapy Perspectives. 35:305-314
Omadacycline (Nuzyra™) is an orally bioavailable, first-in-class, semisynthetic aminomethylcycline antibacterial. A derivative of minocycline, omadacycline has a novel structure that overcomes common mechanisms of tetracycline resistance. In vitro,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1eddbdd699a2806672e02086545324
https://doi.org/10.1007/s40267-019-00634-8
https://doi.org/10.1007/s40267-019-00634-8